Antibody Kinetics and Durability in SARS-CoV-2 mRNA Vaccinated Solid Organ Transplant Recipients

Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review

“…After title and abstract screening, we retained 271 reports. After full-text reading, grey literature and reference list inspection, 162 studies were included from 170 reports (some reports detailed different timepoints of the same study [ [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] ] ( Fig. 1 ).…”

“…Forty-seven studies described immunogenicity across various solid organ transplant populations ( n = 5974), mostly in kidney transplant recipients ( n = 3534, 59.2%) ( Table S5 ) [ 18 , [20] , [21] , [22] , [23] , [24] , [25] , [26] , 29 , 34 , 40 , [56] , [57] , [58] ], [ 62 , 63 , 65 , 66 , 69 , 72 , 73 , 75 , 77 , 79 , 81 , 120 , 126 ], [ [136] , [137] , [138] , [139] , [140] , [141] , [142] , [143] , [144] , [145] , [146] , [147] , [148] , [149] , [150] , [151] , [152] , [153] , [154] , [155] , [156] , [157] , [158] , [159] , [160] ]. Twenty-four of those studies included a control group representing overall 1399 participants [ 21 , 34 , 57 , 63 , 66 , 69 , 72 , 73 , 75 , 79 , ...…”

Six-month Antibody Kinetics and Durability in SARS-CoV-2 mRNA Vaccinated Solid Organ Transplant Recipients

“…We previously reported the overall stability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antispike antibodies in vaccinated solid organ transplant recipients (SOTRs) 3 mo after receiving 2 doses of BNT162b2 or mRNA-1237 vaccines. 1 In the interim, the US Food and Drug Administration fully authorized the BNT162b2 vaccine for people 16 y and older and expanded Emergency Use Authorization to allow for a third dose in immunocompromised individuals. 2 The Centers for Disease Control and Prevention currently recommends an additional dose for mild to moderately immunocompromised patients at least 28 d following mRNA dose 2, but optimal timing for booster doses in SOTRs has not been determined.…”

Antibody kinetics in patients with rheumatic diseases after SARS-CoV-2 mRNA vaccination

“… 1 We previously confirmed a robust SARS-CoV-2 antibody response in most patients with rheumatic and musculoskeletal diseases; however, we found attenuated responses in patients on lymphocyte depleting agents. 2 Although antibody titres among organ transplant recipients 3 months after completion of an mRNA vaccine series were mostly stable, 3 the kinetics of antibody response in other immunosuppressed populations remain to be defined. Here, we present anti-spike antibody titres over a 3-month period in patients with rheumatic and musculoskeletal disease who completed the two-dose SARS-CoV-2 mRNA vaccine series.…”

“…Low-positive antibody response was defined as anti-RBD pan Ig of 0·8–50 units per mL; high-positive antibody response was defined as anti-RBD pan immunoglobulin of more than 50 units per mL. 3 This study was approved by the Johns Hopkins Institutional Review Board (IRB00248540), and patients provided electronic informed consent.…”